$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

$capr Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420415065364 Filed on November 13, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$1.120M	$1.315M	$1.301M
YoY Change	-20.0%	1.03%	1518.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.080M	$970.0K	$820.0K
YoY Change	58.82%	18.29%	46.43%
% of Gross Profit
Research & Development	$3.330M	$3.193M	$1.967M
YoY Change	29.07%	62.32%	94.64%
% of Gross Profit
Depreciation & Amortization	$30.00K	$30.00K	$10.00K
YoY Change	200.0%	200.0%	-200.0%
% of Gross Profit
Operating Expenses	$4.410M	$4.165M	$2.787M
YoY Change	34.86%	49.48%	76.98%
Operating Profit		-$2.851M	-$1.485M
YoY Change		91.94%	-0.6%
Interest Expense	-$60.00K	$61.68K	$60.09K
YoY Change	0.0%	2.65%	157.32%
% of Operating Profit
Other Income/Expense, Net		-$61.39K	-$58.88K
YoY Change		4.26%	15.06%
Pretax Income	-$3.350M	-$2.910M	-$1.540M
YoY Change	73.58%	88.96%	-0.65%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.350M	-$2.912M	-$1.544M
YoY Change	73.58%	88.6%	-0.08%
Net Earnings / Revenue	-299.11%	-221.46%	-118.63%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.055M	-$1.796M	-$1.316M
COMMON SHARES
Basic Shares Outstanding	16.25M shares	16.25M shares	11.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.57M	$17.22M	$10.13M
YoY Change	68.96%	69.96%	14372.5%
Cash & Equivalents	$5.568M	$4.218M	$9.805M
Short-Term Investments	$7.999M	$13.00M	$325.3K
Other Short-Term Assets	$210.0K	$90.00K	$3.810M
YoY Change	-93.48%	-97.64%	9425.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$13.99M	$17.71M	$14.20M
YoY Change	20.52%	24.78%	12923.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$318.6K	$332.1K	$224.5K
YoY Change	38.84%	47.92%	27019.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$70.00K	$130.0K	$60.00K
YoY Change	16.67%	116.67%	1223.04%
Total Long-Term Assets	$2.080M	$2.169M	$2.087M
YoY Change	2.73%	3.93%	38807.01%
TOTAL ASSETS
Total Short-Term Assets	$13.99M	$17.71M	$14.20M
Total Long-Term Assets	$2.080M	$2.169M	$2.087M
Total Assets	$16.07M	$19.88M	$16.28M
YoY Change	17.88%	22.11%	14137.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.880M	$2.890M	$1.910M
YoY Change	35.21%	51.31%	463.01%
Accrued Expenses			$110.0K
YoY Change			-78.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.529M	$6.534M	$6.192M
YoY Change	3.64%	5.52%	423.91%
LONG-TERM LIABILITIES
Long-Term Debt	$9.160M	$9.160M	$9.160M
YoY Change	0.0%	0.0%
Other Long-Term Liabilities	$1.420M	$2.270M	$5.410M
YoY Change	-67.95%	-58.04%	982.0%
Total Long-Term Liabilities	$10.57M	$11.42M	$14.56M
YoY Change	-22.15%	-21.56%	2812.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.529M	$6.534M	$6.192M
Total Long-Term Liabilities	$10.57M	$11.42M	$14.56M
Total Liabilities	$17.10M	$17.96M	$20.75M
YoY Change	-13.98%	-13.48%	1133.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$35.17M	-$31.83M
YoY Change	57.62%
Common Stock	$34.13M	$33.74M	$15.92M
YoY Change	112.44%	111.98%	36472.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.032M	$1.926M	-$4.472M
YoY Change
Total Liabilities & Shareholders Equity	$16.07M	$19.88M	$16.28M
YoY Change	17.88%	22.11%	14137.38%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$3.350M	-$2.912M	-$1.544M
YoY Change	73.58%	88.6%	-0.08%
Depreciation, Depletion And Amortization	$30.00K	$30.00K	$10.00K
YoY Change	200.0%	200.0%	-200.0%
Cash From Operating Activities	-$3.650M	-$3.240M	-$2.230M
YoY Change	70.56%	45.29%	-253.79%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$90.00K	-$70.00K
YoY Change	-100.0%	28.57%	-216.67%
Acquisitions
YoY Change
Other Investing Activities	$5.000M	$2.500M	$0.00
YoY Change	1415.15%		-100.0%
Cash From Investing Activities	$4.990M	$2.420M	-$70.00K
YoY Change	1248.65%	-3557.14%	-95.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	10.00K	520.0K
YoY Change		-98.08%	-208.33%
NET CHANGE
Cash From Operating Activities	-3.650M	-3.240M	-2.230M
Cash From Investing Activities	4.990M	2.420M	-70.00K
Cash From Financing Activities	0.000	10.00K	520.0K
Net Change In Cash	1.340M	-810.0K	-1.780M
YoY Change	-175.71%	-54.49%	313.95%
FREE CASH FLOW
Cash From Operating Activities	-$3.650M	-$3.240M	-$2.230M
Capital Expenditures	$0.00	-$90.00K	-$70.00K
Free Cash Flow	-$3.650M	-$3.150M	-$2.160M
YoY Change	67.43%	45.83%	-255.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	capr	Collaboration Revenue CollaborationRevenue	911458	USD
CY2014Q3	capr	Collaboration Revenue CollaborationRevenue	1041667	USD
CY2014Q3	us-gaap	Revenue From Grants RevenueFromGrants	259800	USD
CY2015Q3	us-gaap	Revenue From Grants RevenueFromGrants	403426	USD
CY2014Q3	us-gaap	Revenues Revenues	1301467	USD
CY2015Q3	us-gaap	Revenues Revenues	1314884	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1966889	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3192657	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	819683	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	972782	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	2786572	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	4165439	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1485105	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2850555	USD
CY2014Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1210	USD
CY2015Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	292	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5200791	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1543986	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	60091	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	61681	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-58881	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61389	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	347482	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1181978	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28352	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79787	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-2911944	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-733	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5414	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1544719	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2906530	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11700136	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16242090	shares
	capr	Collaboration Revenue CollaborationRevenue	2864583	USD
	capr	Collaboration Revenue CollaborationRevenue	3125001	USD
	us-gaap	Revenue From Grants RevenueFromGrants	259800	USD
	us-gaap	Revenue From Grants RevenueFromGrants	1529669	USD
	us-gaap	Revenues Revenues	3384801	USD
	us-gaap	Revenues Revenues	4394252	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5203766	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10426548	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2332579	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3294601	USD
	us-gaap	Operating Expenses OperatingExpenses	7536345	USD
	us-gaap	Operating Expenses OperatingExpenses	13721149	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4151544	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9326897	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	3129	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	723	USD
	us-gaap	Interest Expense InterestExpense	140122	USD
	us-gaap	Interest Expense InterestExpense	185043	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-136993	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-184320	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4288537	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9511217	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-627	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11949	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4289164	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9499268	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11694004	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15783224	shares
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	1925666	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16446218	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	45461	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1181978	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	2297801	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-2977024	USD
	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	260436	USD
	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	43192	USD
	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-117663	USD
	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-143047	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	29592	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	77881	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16446218	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	303881	shares
	capr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	52650	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.40
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	95792	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	609423	USD
	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	-123142	USD
	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	145945	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	140122	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	185043	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9374999	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2864583	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	3104902	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7174626	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17987496	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	549	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	146685	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124383	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-234394	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-13133409	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5205390	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16491679	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1729537	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8034765	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9805435	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4218409	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	64514	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	21530	USD
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	23744	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3816356	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8075898	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	45461	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4599	USD
CY2014Q4	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	433712	USD
	us-gaap	Payments For Royalties PaymentsForRoyalties	20000	EUR
CY2014Q1	capr	Proceeds From Development Fee ProceedsFromDevelopmentFee	12500000	USD
CY2013Q4	capr	Additional Milestone Payments To Be Received Contingent Upon Exercise Of Options AdditionalMilestonePaymentsToBeReceivedContingentUponExerciseOfOptions	325000000	USD
CY2015Q3	capr	Leases Monthly Payments For First Twelve Months LeasesMonthlyPaymentsForFirstTwelveMonths	16620	USD
CY2015Q3	capr	Leases Monthly Payments For Second Twelve Months LeasesMonthlyPaymentsForSecondTwelveMonths	17285	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	17957	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	21420	USD
CY2015Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	16700000	USD
	capr	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	0	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.02
	capr	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	0
	capr	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	47.00
	capr	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	15401	shares
	capr	Class Of Warrant Or Right Exercised Weighted Average Exercise Price ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice	2.27
CY2015Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.27
CY2015Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	235830	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.11
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.83
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.86
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	266927	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	148487	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1173390	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	340693	USD
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4800000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M12D
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4166666	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1822916	USD
CY2014Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	9155857	USD
CY2015Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	9155857	USD
CY2014Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	258639	USD
CY2015Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	443682	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13581162	USD
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16254985	shares
CY2015Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	30000	USD
CY2015Q3	us-gaap	Marketable Securities MarketableSecurities	12999445	USD
CY2015Q3	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	17200000	USD
CY2014Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	8000000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2839045	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.523
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1658822	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	4.25
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7050000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36562	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8282	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1500000	USD
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5311693	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5311693	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6273197	shares
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2015Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	12999445	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2977024	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2014Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	360233	USD
CY2015Q3	us-gaap	Grants Receivable Current GrantsReceivableCurrent	403425	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	235523	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	92476	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	11607545	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	17713755	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	229455	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332143	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	239752	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	203190	USD
CY2014Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2015Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2014Q4	us-gaap	Other Assets OtherAssets	55320	USD
CY2015Q3	us-gaap	Other Assets OtherAssets	133201	USD
CY2014Q4	us-gaap	Assets Assets	13632072	USD
CY2015Q3	us-gaap	Assets Assets	19882289	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1699254	USD
CY2015Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2308677	USD
CY2015Q3	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	579657	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4166667	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3645834	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6299633	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6534168	USD
CY2015Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11422455	USD
CY2014Q4	us-gaap	Liabilities Liabilities	19880795	USD
CY2015Q3	us-gaap	Liabilities Liabilities	17956623	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	16054697	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	33723806	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11949	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13632072	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19882289	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	16255	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	11707	USD
	dei	Document Type DocumentType	10-Q
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31826344	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22315127	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Trading Symbol TradingSymbol	CAPR
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16254985	shares
CY2015Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	86492	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	49930	USD
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	CAPRICOR THERAPEUTICS, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001133869
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16254985	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11707051	shares
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	43276	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	6496	USD
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6273197	shares
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	124383	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	364866	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	96750	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	585999	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022	pure
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	12187	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	48749	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	48749	USD
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	43732	USD
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11707051	shares
CY2014Q4	us-gaap	Line Of Credit LineOfCredit	9155857	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure

Files In Submission

Name	View Source	Status
0001144204-15-065364-index-headers.html	Edgar Link	pending
0001144204-15-065364-index.html	Edgar Link	pending
0001144204-15-065364.txt	Edgar Link	pending
0001144204-15-065364-xbrl.zip	Edgar Link	pending
capr-20150930.xml	Edgar Link	completed
capr-20150930.xsd	Edgar Link	pending
capr-20150930_cal.xml	Edgar Link	unprocessable
capr-20150930_def.xml	Edgar Link	unprocessable
capr-20150930_lab.xml	Edgar Link	unprocessable
capr-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v423417_10q.htm	Edgar Link	pending
v423417_ex10-1.htm	Edgar Link	pending
v423417_ex10-2.htm	Edgar Link	pending
v423417_ex31-1.htm	Edgar Link	pending
v423417_ex31-2.htm	Edgar Link	pending
v423417_ex32-1.htm	Edgar Link	pending
v423417_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

2015 Q4 Form 10-Q Financial Statement

#000114420415065364 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR CAPRICOR THERAPEUTICS, INC. Stock $capr

2015 Q4 Form 10-Q Financial Statement

#000114420415065364 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr